
    
      A total of 200 infertile women with at least two previous IVF failures will enroll in this
      prospective randomized clinical trial study and will randomly be divided into two groups.
      Random permuted blocks with a block size of 4 will be used to ensure randomization and
      complete allocation concealment.

      The study protocol will be assessed by an independent institutional review board and Royan
      ethics committee.

      Ovarian stimulation protocol will include the use of a GnRH agonist (Superfact; Aventis
      Pharma Deutshlan, Frankfurt, Germany) administered in the long (down-regulation) protocol and
      the subsequent addition of FSH (Gonal F, Sereno, Switzerland). Embryos will be initially
      cultured in G1.V5 medium) Vitrolife-Sweden)TM on day 1 and 2, being transferred from this
      medium to G2.V5 ) Vitrolife-Sweden)TM on day 3. Embryos will be transferred on day 5,
      depending on the degree of expansion of the blastocyst.

      Main outcome measures will be implantation, clinical pregnancy and live birth rates.
    
  